New blood marker may help spot deadliest sepsis cases
NCT ID NCT03682003
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether measuring hepcidin, a hormone that controls iron levels, in the blood of 114 patients with severe sepsis or septic shock could predict who would die within 28 days. Researchers also tracked deaths at 90 days and infections acquired in the hospital. The goal is to find a reliable biomarker to guide early, aggressive treatment for the sickest patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a simple blood test that helps doctors quickly identify which sepsis patients are at highest risk, enabling earlier and more tailored treatment.
What could go wrong
This is a small, completed observational study, not a treatment trial. The findings may not be strong enough to change practice, and many other sepsis biomarkers have failed to prove useful in routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE SEPSIS OR SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rennes University Hospital
Rennes, France